NYSE · ALC
Alcon Inc.
$71.13+$1.30 (+1.86%)
Alcon Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.84% below the high.
Loading market information…
NASDAQ · SGP · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
SpyGlass Pharma, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
SpyGlass Pharma, Inc. Common Stock’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.66. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow SpyGlass Pharma, Inc. Common Stock’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $38.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$71.13+$1.30 (+1.86%)
Alcon Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.84% below the high.
$242.48+$61.05 (+33.65%)
Glaukos Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.51% below the high.
$20.40$0.00 (0.0%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.49% below the high.
$7.31+$0.02 (+0.27%)
Ocular Therapeutix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.54% below the high.
$25.24+$0.63 (+2.56%)
STAAR Surgical Company’s quoted price sits in the lower half of its reported 52-week range, 29.63% below the high.
$9.57+$0.33 (+3.57%)
Sight Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.47% below the high.
$8.24+$0.26 (+3.26%)
Oculis Holding AG’s quoted price sits in the lower half of its reported 52-week range, 76.1% below the high.
$5.05+$0.15 (+3.06%)
RxSight, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.8% below the high.
